Reason analysis of drug resistance of aspirin applied to secondary prevention of cerebral infarction and study of intervention effect of clopidogrel
Author(s): LI Xin, LIU Lan-xing, LIU Yi-qiong
Pages: 490-493
Year: 2017 Issue: 8
Journal: Journal of Brain and Nervous Diseases
Keyword: Cerebral infarction; Two level prevention; Aspirin resistance; Clopidogrel;
Abstract: Objective To analyze the reason for drug resistance of aspirin applied to secondary prevention of cerebral infarction and intervention effect of clopidogrel. Method A total of two hundred and fifty-six cases of patients with cerebral infarction admitted to our hospital from January 2014 to September 2015 were selected and included into objects of study. All patients began to take aspirin on admission day. After 7 days of drug administration, the platelet aggregation rate was measured, a total of sixty-two cases of patients with aspirin resistance(AR)or aspirin semi-resistance(ASR)were screened, and relevant factors giving rise to AR were analyzed. The sixty-two cases of patients were randomly divided into observation group and control group according to the random number table method,with thirty-one cases in each group. Patients in the control group continued to take aspirin, and those in the observation group took clopidogrel in combination with aspirin. Changes in platelet aggregation rate, relapse of cerebral infarction and hemorrhage of patients in the two groups were observed. Results Among the two hundred and fifty-six cases of patients with cerebral infarction, sixty-two cases were attacked by AR, and the incidence rate was 24.22%. Female, diabetes and level of low density lipoprotein(LDL)in patients in AR Group and ASR Group were significantly higher than in aspirin sensitive(AS)group(t/ x2=4.396, 4.083, 11.191,P<0.05); at 7d and 14d after treatment, the platelet aggregation rate in the observation group was significantly lower than that in the control group(t=10.578, 10.466,P<0.05); after 6 months(July 2014 to March 2016)and 12 months(December 2014 to August 2016)of follow-up visit, recurrent cerebral infarction rate in patients in the observation group was significantly lower than in the control group(3.23% vs 19.38%, 3.23% vs 22.58%)( x2=4.026, 5.167,P<0.05). Conclusion Female, diabetes and high and low density lipoprotein are high risk factors causing AR in secondary prevention of cerebral infarction. Clopidogrel in combination with aspirin therapy can reduce platelet aggregation rate and prevent the relapse of cerebral infarction.
Pages: 490-493
Year: 2017 Issue: 8
Journal: Journal of Brain and Nervous Diseases
Keyword: Cerebral infarction; Two level prevention; Aspirin resistance; Clopidogrel;
Abstract: Objective To analyze the reason for drug resistance of aspirin applied to secondary prevention of cerebral infarction and intervention effect of clopidogrel. Method A total of two hundred and fifty-six cases of patients with cerebral infarction admitted to our hospital from January 2014 to September 2015 were selected and included into objects of study. All patients began to take aspirin on admission day. After 7 days of drug administration, the platelet aggregation rate was measured, a total of sixty-two cases of patients with aspirin resistance(AR)or aspirin semi-resistance(ASR)were screened, and relevant factors giving rise to AR were analyzed. The sixty-two cases of patients were randomly divided into observation group and control group according to the random number table method,with thirty-one cases in each group. Patients in the control group continued to take aspirin, and those in the observation group took clopidogrel in combination with aspirin. Changes in platelet aggregation rate, relapse of cerebral infarction and hemorrhage of patients in the two groups were observed. Results Among the two hundred and fifty-six cases of patients with cerebral infarction, sixty-two cases were attacked by AR, and the incidence rate was 24.22%. Female, diabetes and level of low density lipoprotein(LDL)in patients in AR Group and ASR Group were significantly higher than in aspirin sensitive(AS)group(t/ x2=4.396, 4.083, 11.191,P<0.05); at 7d and 14d after treatment, the platelet aggregation rate in the observation group was significantly lower than that in the control group(t=10.578, 10.466,P<0.05); after 6 months(July 2014 to March 2016)and 12 months(December 2014 to August 2016)of follow-up visit, recurrent cerebral infarction rate in patients in the observation group was significantly lower than in the control group(3.23% vs 19.38%, 3.23% vs 22.58%)( x2=4.026, 5.167,P<0.05). Conclusion Female, diabetes and high and low density lipoprotein are high risk factors causing AR in secondary prevention of cerebral infarction. Clopidogrel in combination with aspirin therapy can reduce platelet aggregation rate and prevent the relapse of cerebral infarction.
Related Articles